A Long-Term Follow-Up Study of Participants Exposed to REACT
Recruiting · NCT05918523 · Observational (researchers observe without assigning treatment) · Lead sponsor: Prokidney
View the official record on ClinicalTrials.gov →Interventions studied
Renal Autologous Cell Therapy (REACT)
What this trial is about
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Who can take part
Age range
30 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.
Exclusion criteria
- The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.
Where it is running
1 location listed across 1 US state.
- Boise Kidney & Hypertension Institute - Meridian, Idaho, United States